Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
DENVER, Feb. 15, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its fourth quarter and full-year 2016 financial results on Friday, March 3, 2017, before the opening of the U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Jeffrey M. Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | Friday, March 3, 2017 | ||
| Time | 9:00 a.m. EST | ||
| Toll free (U.S.) | (888) 372-9592 | ||
| Webcast (live and replay) | www.bioscrip.com | ||
A replay of the conference call will be available for one week after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 5266355.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts: Jeffrey M. Kreger Chief Financial Officer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]
